{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:35:29Z","timestamp":1794969329746,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate progression of macular telangiectasia Type 2 lesions and their correlation with visual acuity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>An international multicenter prospective study with annual examinations including best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, and optical coherence tomography images graded centrally. Mixed models were used to estimate progression rates, and a generalized linear model to compute the relative risk of BCVA loss, loss of ellipsoid zone (EZ) reflectivity, development of pigment plaques, or neovascularization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One thousand and fourteen eyes of 507 participants were followed for 4.2 \u00b1 1.6 years. Best-corrected visual acuity decreased 1.07 \u00b1 0.05 letters (mean \u00b1 SE) per year. Of all eyes, 15% lost \u226515 letters after 5 years. Of the eyes without EZ loss, 76% developed a noncentral loss. Of the eyes with noncentral loss, 45% progressed to central EZ loss. The rate of BCVA loss in eyes with noncentral EZ loss at baseline was similar to eyes without EZ loss. The rate of BCVA loss was significantly higher in eyes with central EZ loss at baseline (\u22121.40 \u00b1 0.14 letters, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Ellipsoid zone loss is frequently found in macular telangiectasia Type 2 and is an important structural component reflecting visual function. Its presence in the fovea significantly correlates with worse visual prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001697","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T09:46:47Z","timestamp":1494668807000},"page":"S8-S13","source":"Crossref","is-referenced-by-count":73,"title":["CORRELATION OF CLINICAL AND STRUCTURAL PROGRESSION WITH VISUAL ACUITY LOSS IN MACULAR TELANGIECTASIA TYPE 2"],"prefix":"10.1097","volume":"38","author":[{"given":"Tunde","family":"Peto","sequence":"first","affiliation":[{"name":"Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom;"},{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjebo F. C.","family":"Heeren","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom;"},{"name":"University Eye Hospital, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[{"name":"The Emmes Corporation, Rockville, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc B.","family":"Sallo","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Leung","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[{"name":"National Eye Institute, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Bird","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MacTel Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archopht.1982.01030030773010","article-title":"Idiopathic juxtafoveolar retinal telangiectasis","volume":"100","author":"Gass","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","article-title":"Macular telangiectasia type 2","volume":"34","author":"Charbel Issa","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1167\/iovs.12-10765","article-title":"The IS\/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia","volume":"53","author":"Sallo","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/IAE.0000000000000863","article-title":"Very early disease manifestations of macular telangiectasia type 2","volume":"36","author":"Charbel Issa","year":"2016","journal-title":"Retina"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.ophtha.2010.04.001","article-title":"Perifoveal muller cell depletion in a case of macular telangiectasia type 2","volume":"117","author":"Powner","year":"2010","journal-title":"Ophthalmology"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.ophtha.2013.04.013","article-title":"Loss of Muller's cells and photoreceptors in macular telangiectasia type 2","volume":"120","author":"Powner","year":"2013","journal-title":"Ophthalmology"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamaophthalmol.2015.1796","article-title":"Macular telangiectasia type 2 without clinically detectable vasculopathy","volume":"133","author":"Gillies","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"15715","DOI":"10.1523\/JNEUROSCI.2841-12.2012","article-title":"Conditional Mullercell ablation causes independent neuronal and vascular pathologies in a novel transgenic model","volume":"32","author":"Shen","year":"2012","journal-title":"J Neurosci"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/sj.eye.6702985","article-title":"A case of idiopathic perifoveal Telangiectasia preceded by features of cone dystrophy","volume":"21","author":"Barthelmes","year":"2007","journal-title":"Eye (Lond)"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1167\/iovs.07-0636","article-title":"Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia","volume":"49","author":"Charbel Issa","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2010.11.019","article-title":"Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study","volume":"151","author":"Charbel Issa","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1097\/IAE.0000000000000715","article-title":"Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2","volume":"35","author":"Kupitz","year":"2015","journal-title":"Retina"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31824690a8","article-title":"Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial","volume":"32","author":"Toy","year":"2012","journal-title":"Retina"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/IAE.0000000000000203","article-title":"Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization","volume":"34","author":"Do","year":"2014","journal-title":"Retina"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1167\/iovs.15-16915","article-title":"Progression of vision loss in macular telangiectasia type 2","volume":"56","author":"Heeren","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2014an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R18-20230816","first-page":"761","article-title":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early treatment diabetic retinopathy study report number 2. Early treatment diabetic retinopathy study research group","volume":"94","year":"1987","journal-title":"Ophthalmology"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ophtha.2011.05.022","article-title":"Retinal crystals in type 2 idiopathic macular telangiectasia","volume":"118","author":"Sallo","year":"2011","journal-title":"Ophthalmology"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1167\/iovs.06-1272","article-title":"Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia","volume":"48","author":"Charbel Issa","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1167\/iovs.12-10580","article-title":"\u201cEn face\u201d OCT imaging of the IS\/OS junction line in type 2 idiopathic macular telangiectasia","volume":"53","author":"Sallo","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1167\/iovs.14-15576","article-title":"Adaptive optics microperimetry and OCT images show preserved function and recovery of cone visibility in macular telangiectasia type 2 retinal lesions","volume":"56","author":"Wang","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ajo.2009.04.030","article-title":"Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry","volume":"148","author":"Wong","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"e12864","DOI":"10.1371\/journal.pone.0012864","article-title":"Structure-function correlation of the human central retina","volume":"5","author":"Charbel Issa","year":"2010","journal-title":"PLoS One"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201801001-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T19:03:40Z","timestamp":1692212620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201801001-00003"}},"subtitle":["MacTel Project Report No. 6\u2013The MacTel Research Group"],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001697","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}